Trivitron Healthcare, a medical technology company specialising in in-vitro diagnostic (IVD) devices, has acquired a 60% stake in Turkish firm Bome Sanayi Urunleri Dis. Tic. Ltd Sti., for a purchase consideration of €5m ($5.52m). The remaining stake in the company will be held by the promoters.
Go deeper with GlobalData
The acquisition allows Trivitron to get direct access to the Turkish, Middle Eastern, African, South and South East Asian markets, through which it can expand its growth.
Corin Orthopaedics Holdings intends to acquire Wright Medical Group’s large joints (hip / knee) business for a purchase consideration of approximately $33m.
Corin has made a binding offer, according to which it will acquire all of the legacy tornier large joints business, which, following the transaction, will continue to be headquartered in Montbonnot, France.
See Also:
The transaction, which is expected to close between Q3 and Q4 of 2016, will help Wright Medical to focus on extremities and biologics markets and to expand its growth profile.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNichi-Iko Pharmaceutical, through its wholly-owned subsidiary Shepard Vision (Merger Sub), will acquire Sagent Pharmaceuticals for a cash consideration of $736m. The acquisition will be financed through bank loans and available cash.
The acquisition, which will close in Q2 of Nichi-Iko’s fiscal year ending March 2017, will enable the company to commercialise its biosimilar product pipeline, to further expand its platform in the US market, and to enhance its presence in injectables.
Ossen Innovation intends to acquire 90.27% stake in San MediTech (Huzhou) from America-Asia Diabetes Research Foundation.
Ossen has signed a non-binding letter of intent (LOI), according to which it will acquire all issued and outstanding equity interests of the Research Foundation in San MediTech and in exchange will issue 81,243,000 of its ordinary shares.
Image: A handshake. Photo: courtesy of Flazingo Photos.
